Sugi Predict

Sugi Predict / Targets / RASGRP1

RASGRP1

RAS guanyl-releasing protein 1 · O95267 · RASGRP1 on Sugi Atlas →

30 patent compounds predicted against RASGRP1, 20 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL25138526 SCHEMBL25138526 0.84 7/20
SCHEMBL9458678 SCHEMBL9458678 0.50 7/20
SCHEMBL25138743 SCHEMBL25138743 0.81 6/20
SCHEMBL25138753 SCHEMBL25138753 0.85 5/20
SCHEMBL25138528 SCHEMBL25138528 0.85 5/20
SCHEMBL25138631 SCHEMBL25138631 0.85 5/20
SCHEMBL25138756 SCHEMBL25138756 0.84 5/20
SCHEMBL25138755 SCHEMBL25138755 0.82 4/20
SCHEMBL25138532 SCHEMBL25138532 0.81 4/20
SCHEMBL25138629 SCHEMBL25138629 0.81 4/20
SCHEMBL25138527 SCHEMBL25138527 0.81 4/20
SCHEMBL6379635 SCHEMBL6379635 0.52 1/20
SCHEMBL28991624 SCHEMBL28991624 0.50 1/20
SCHEMBL7300604 SCHEMBL7300604 0.47 1/20
SCHEMBL7300751 SCHEMBL7300751 0.46 1/20
SCHEMBL7294320 SCHEMBL7294320 0.46 1/20
SCHEMBL4769477 SCHEMBL4769477 0.45 1/20
SCHEMBL22734013 SCHEMBL22734013 0.45 1/20
SCHEMBL392972 SCHEMBL392972 0.41 1/20
SCHEMBL7295769 SCHEMBL7295769 0.41 1/20

Clinical trials — most relevant to RASGRP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy PHASE2RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma PHASE2COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
RAS-Peptide-Profile Study in Healthy Male Subjects PHASE1COMPLETED
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Prevalence and Characterization of Pain in RASopathies nanUNKNOWN
Long QT Syndrome-Population Genetics and Cardiac Studies nanCOMPLETED
Characterisation of Gene Variants in the Angiogenic Pathway nanUNKNOWN
RASopathy Biorepository nanRECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Genetics of Hypertension in Blacks nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Renal Artery Dopplers in Twin Twin Transfusion Syndrome nanCOMPLETED
Thrombin Regulated Platelet Activation nanCOMPLETED
Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles nanACTIVE_NOT_RECRUITING
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer nanRECRUITING
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
CML Pediatric ITK Response According to Molecular Identification at Diagnosis nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RASGRP1 binder may also engage these)

ProteinNameSimilarity
Q9Z1S3 — 1.000 Q9Z1S3 →
Q9R1K8 — 0.998 Q9R1K8 →
A4IJ06 — 0.992 A4IJ06 →
Q6NTL4 — 0.989 Q6NTL4 →
Q69ZK0 — 0.979 Q69ZK0 →
Q8C0Q9 — 0.978 Q8C0Q9 →
Q3LAC4 — 0.977 Q3LAC4 →
Q8TCU6 — 0.975 Q8TCU6 →
A2AWP8 — 0.975 A2AWP8 →
Q66H91 — 0.975 Q66H91 →
O88842 — 0.974 O88842 →
Q9HCE6 — 0.973 Q9HCE6 →
Q66T02 — 0.973 Q66T02 →
Q8N5V2 — 0.973 Q8N5V2 →
Q9JLQ2 — 0.973 Q9JLQ2 →
Q9UPU7 — 0.972 Q9UPU7 →
Q14CM0 — 0.972 Q14CM0 →
Q3UGM2 — 0.972 Q3UGM2 →
Q70Z35 — 0.972 Q70Z35 →
Q8CHT1 — 0.972 Q8CHT1 →
Q14161 — 0.971 Q14161 →
Q5JSP0 — 0.971 Q5JSP0 →
Q6ZR37 — 0.970 Q6ZR37 →
Q5BKC9 — 0.970 Q5BKC9 →
P49797 — 0.970 P49797 →
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 0.969 landscape →
F1LXF1 — 0.969 F1LXF1 →
P0C6S7 — 0.969 P0C6S7 →
Q9Z272 — 0.969 Q9Z272 →
Q8C190 — 0.969 Q8C190 →